In a new trial, patients newly diagnosed with acute myeloid leukemia (AML) fared significantly better with a combined regimen ...

RMAT designation indicates that SENTI-202 has the potential to address unmet medical needs for patients with Relapsed/Refractory (R/R) Acute ...

ORLANDO -- Azacitidine and venetoclax (Venclexta) significantly improved event-free survival (EFS) in newly diagnosed fit ...

Review of current and emerging treatments for older adults with acute myeloid leukemia, highlighting venetoclax plus ...

A new generation of targeted treatments and gentler chemotherapy options for older adults with a new diagnosis of acute ...

Measurable residual disease after induction therapy may serve as an individual-level predictor of survival among patients ...

Venclexta-azacitidine combination offered better responses with less hospitalization and lower symptom burden compared with ...

NPM1 minimal residual disease (MRD) positivity before allogeneic hematopoietic cell transplantation is linked to higher relapse rates and lower overall survival in patients with acute myeloid leukemia ...

Continues to drive enrollment with increase to 78% now consentedBlinded response activity tracking within expected range ...

In updated 2025 American Society of Hematology guidelines, recommendations are presented for the management of newly ...

High-dose daunorubicin improved complete response rates in patients aged 60 and younger and survival in those younger than 50. Despite considerable advances during the past 20 years in the diagnostic ...